Review Article
The need for novel influenza vaccines in low- and middle-income countries: A narrative review
Julia R. Spinardia,
, Karan B. Thakkarb, Verna L. Welchc, Oladayo Jagund, Moe H. Kyawe
Corresponding author
a Vaccine Medical and Scientific Affairs, Emerging Markets, Pfizer Inc., São Paulo, SP, Brazil
b Vaccine Medical and Scientific Affairs, Emerging Markets, Pfizer Inc., Singapore, Singapore
c Vaccine Medical and Scientific Affairs, Pfizer Inc., Pennsylvania, USA
d Real World Strategy and Innovation, IQVIA Inc., New Jersey, USA
e Vaccine Medical and Scientific Affairs, Emerging Markets, Pfizer Inc., Virginia, USA
Read
3979
Timeswas read the article
846
Total PDF
3133
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 11 | 758 | 211 | 969 |
| 2025 10 | 489 | 124 | 613 |
| 2025 9 | 501 | 77 | 578 |
| 2025 8 | 236 | 74 | 310 |
| 2025 7 | 193 | 54 | 247 |
| 2025 6 | 155 | 31 | 186 |
| 2025 5 | 111 | 50 | 161 |
| 2025 4 | 73 | 42 | 115 |
| 2025 3 | 95 | 32 | 127 |
| 2025 2 | 86 | 29 | 115 |
| 2025 1 | 118 | 49 | 167 |
| 2024 12 | 318 | 73 | 391 |
